Atrial Flutter Management

Introduction to Rate Control

The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend beta blockers, including carvedilol, as Class I (Level B-R) therapy for acute rate control in hemodynamically stable patients with atrial flutter, achieving rate control through reduction of sympathetic tone and direct effects on the AV node 1
Beta blockers, as a class, were the most effective drug class for rate control in the AFFIRM study, achieving heart rate endpoints in 70% of patients compared with 54% for calcium channel blockers 2
Non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, are equally recommended for rate control when beta blockers are ineffective or contraindicated 1

Carvedilol effectively lowers ventricular rate at rest and during exercise in patients with atrial arrhythmias, with studies showing its effectiveness in rate control 3
Carvedilol has particular advantages in patients with atrial flutter and heart failure, and is effective for rate control when added to digoxin in heart failure patients with atrial fibrillation 2
The American College of Cardiology, American Heart Association, and Heart Rhythm Society note that carvedilol should be initiated cautiously in patients with reduced ejection fraction 2

The American College of Cardiology, American Heart Association, and Heart Rhythm Society list decompensated heart failure and reactive airway disease as contraindications for carvedilol 1
Potential side effects of carvedilol include hypotension, bradycardia, heart block, and potential worsening of heart failure 3

For rhythm control, cardioversion or catheter ablation are preferred over pharmacological therapy, and in hemodynamically unstable patients, synchronized cardioversion is recommended 1
The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend catheter ablation as a preferred option for long-term management of atrial flutter over pharmacological therapy 1
In patients with atrial flutter and systolic heart failure, intravenous amiodarone can be useful for acute ventricular rate control when beta blockers are contraindicated or ineffective, with a Class IIa recommendation 4, 1
In patients with pre-excitation syndrome, beta blockers, diltiazem, verapamil, and digoxin should be avoided as they may accelerate ventricular rates and potentially lead to ventricular fibrillation 1, 5
Catheter ablation of CTI-dependent atrial flutter is often preferred to long-term pharmacological therapy for patients with symptomatic or recurrent atrial flutter, with a Class I recommendation 4, 1, 6
Acute antithrombotic therapy is recommended in patients with atrial flutter to align with recommended antithrombotic therapy for patients with AF, with a Class I recommendation 4, 1

Atrial flutter can be more difficult to achieve rate control compared to atrial fibrillation due to the relatively slower atrial rate resulting in more rapid AV nodal conduction 1
Higher doses of rate-controlling medications, and often a combination of agents, may be needed to achieve adequate rate control in atrial flutter 1
Synchronized cardioversion is recommended for acute treatment of patients with atrial flutter who are hemodynamically unstable 4
In heart failure patients, beta blockers are generally preferred for rate control in atrial flutter 1